Fig. 7.

The galectin-3 specific inhibitor GB1107 significantly reduces tumor burden in orthotopic gastric cancer tumor-bearing mice. a–d Development of the gastric cancer orthotopic mouse model. Mice were given 100 μL of either Oral-B solution (control) or Oral-B solution containing 5 or 10 mg/kg GB1107 by oral gavage three times per week. a Tumor size as estimated by luciferase bioluminescent imaging. b Mice were sacrificed, and the orthotopic gastric tumor was removed for analysis. The arrow indicates the mouse stomach, and the dotted line encircles the orthotopic gastric cancer tumor. c, d Tumor volume c and weight d at 28 days after starting GB1107 treatment. e Levels of galectin-3, pSTAT3(Tyr705), STAT3, and β-catenin in the stomach of mice treated with Oral-B solution or GB1107. f Experimental scheme of this study. Galectin-3 interacts with STAT3 and alters STAT3 phosphorylation. STAT3 phosphorylation at Tyr705 was induced by WNT signaling-induced galectin-3 expression. These complexes then regulate survivin and cyclin D1 transcriptional activity downstream of STAT3. Gal3 galectin-3